FIGURE 1.

Gelsolin (GSN) levels are decreased in glioblastoma (GBM) and are positively related to progression‐free survival (PFS)/overall survival (OS) in patients with GBM. A, GSN expression was tested in 5 pairs of normal brain (NB) tissue and GBM tissue by western blotting. P, patient. B, Expression of NB (n = 8) and GBM (n = 39) is evaluated by western blotting based on band intensity. ***P < .001. A significant difference between the 2 groups is shown. Significance was evaluated by Student’s t test. C, Immunohistochemistry was carried out on NB (n = 2) and GBM (n = 13) sections. Red arrow indicates the cell expressing GSN. Magnification, 200×. D, Dual stain immunofluorescence was carried out on NB sections with GSN (green), glial fibrillary acidic protein (GFAP; red), and DAPI (blue). White arrows indicate the cell expressing GSN and GFAP. Magnification, 200×. E, Kaplan‐Meier survival curves indicate that higher expression of GSN results in longer PFS (P = .0277) and OS (P = .0321). Log‐rank (Mantel‐Cox) analysis